Critical Limb Ischemia (CLI) Treatment Market Size, Share and Growth Outlook, 2026

Critical Limb Ischemia (CLI) Treatment Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Critical Limb Ischemia (CLI) Treatment Market size is forecast to increase from $1.81 Billion in 2026 to $3.02 Billion in 2034 at a CAGR of 6.6% between 2026 and 2034.

The Critical Limb Ischemia (CLI) Treatment market report provides detailed analysis and outlook of Critical Limb Ischemia (CLI) Treatment segments including By Treatment Modality (Peripheral Revascularization Devices, Pharmacological, Regenerative & Cell-Based Therapies), By Device Type (Peripheral Dilatation Balloons, Vascular and Drug-Eluting Stents, Atherectomy Systems & Catheters, Embolic Protection Devices), By Drug Class (Antiplatelet Drugs, Antithrombotic, Lipid-Lowering Agents, Antihypertensive Agents), By Route of Drug Administration (Oral Administration, Parenteral ), By End-User (Hospitals and Tertiary Medical Centers, Ambulatory Surgical Centers, Specialty Vascular and Wound-Care Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Critical Limb Ischemia (CLI) Treatment Industry Overview

Gene Therapy Innovation Creating New Opportunities for Limb Preservation

The critical limb ischemia treatment industry is witnessing significant advancements in regenerative and gene-based therapies aimed at addressing severe vascular disease in patients with limited treatment options. Recent Phase 2 clinical trial results published in The Lancet demonstrated promising outcomes for a novel angiogenic gene therapy designed for patients with "no-option" critical limb ischemia. The investigational treatment utilizes localized delivery of growth factors to stimulate the formation of collateral blood vessels, thereby improving blood flow to ischemic tissues. This approach has the potential to reduce amputation risk among high-risk patients who are not suitable candidates for conventional surgical or endovascular interventions. The emergence of angiogenic gene therapies reflects growing interest in regenerative medicine strategies that target the underlying causes of tissue ischemia while supporting long-term limb salvage and vascular restoration.

Advanced Endovascular Technologies Expanding Minimally Invasive Treatment Options

Technological innovation continues to strengthen the critical limb ischemia treatment industry through the introduction of specialized endovascular devices designed to address complex peripheral artery disease. Boston Scientific Corporation received FDA clearance for a new drug-coated balloon specifically developed for the treatment of complex below-the-knee arterial lesions commonly encountered in CLI patients. These lesions are often difficult to treat due to their location, severity, and high risk of restenosis. Drug-coated balloon technology enables targeted delivery of therapeutic agents directly to diseased vessels while minimizing the need for permanent implants. The availability of dedicated below-the-knee treatment devices expands the range of minimally invasive options available to vascular specialists and supports improved management of distal arterial disease. Such innovations are contributing to enhanced procedural outcomes and greater preservation of limb function.

Multidisciplinary Centers of Excellence Improving Patient Outcomes

The treatment landscape for critical limb ischemia is increasingly centered on collaborative, multidisciplinary care models. Recent cardiovascular association reports highlight the growing establishment of dedicated CLI Centers of Excellence that bring together expertise from vascular surgery, interventional radiology, wound care, and related specialties. These specialized centers are designed to provide comprehensive evaluation, rapid intervention, and coordinated long-term management for patients with advanced peripheral artery disease. By integrating multiple clinical disciplines within a unified treatment framework, these centers aim to improve limb salvage rates, reduce amputation risk, and enhance overall patient outcomes. The increasing adoption of multidisciplinary care pathways reflects broader recognition that successful CLI management requires a combination of revascularization strategies, advanced wound care, infection control, and ongoing vascular surveillance. As healthcare systems continue to prioritize value-based care, dedicated CLI treatment centers are emerging as important models for improving quality and continuity of care for high-risk patient populations.

Critical Limb Ischemia (CLI) Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Critical Limb Ischemia (CLI) Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical LLC, Becton, Dickinson and Company (BD), Koninklijke Philips N.V., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Terumo Corporation, Cardiovascular Systems, Inc. (An Abbott Company), Biotronik SE & Co. KG. The Critical Limb Ischemia (CLI) Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Critical Limb Ischemia (CLI) Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Critical Limb Ischemia (CLI) Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Critical Limb Ischemia (CLI) Treatment companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Critical Limb Ischemia (CLI) Treatment markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Critical Limb Ischemia (CLI) Treatment Market Competitive Benchmarking and Company Analysis

Leading companies in Critical Limb Ischemia (CLI) Treatment industry include- Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Cook Medical LLC, Becton, Dickinson and Company (BD), Koninklijke Philips N.V., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Terumo Corporation, Cardiovascular Systems, Inc. (An Abbott Company), Biotronik SE & Co. KG. The Critical Limb Ischemia (CLI) Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Critical Limb Ischemia (CLI) Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Critical Limb Ischemia (CLI) Treatment market remains one of the strongest-performing segments in the country.
The US Critical Limb Ischemia (CLI) Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Critical Limb Ischemia (CLI) Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Critical Limb Ischemia (CLI) Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Critical Limb Ischemia (CLI) Treatment markets

Canada's strong Critical Limb Ischemia (CLI) Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Critical Limb Ischemia (CLI) Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Critical Limb Ischemia (CLI) Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Critical Limb Ischemia (CLI) Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Critical Limb Ischemia (CLI) Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Critical Limb Ischemia (CLI) Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Critical Limb Ischemia (CLI) Treatment market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Critical Limb Ischemia (CLI) Treatment sales through 2034

France Critical Limb Ischemia (CLI) Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Critical Limb Ischemia (CLI) Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Critical Limb Ischemia (CLI) Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Critical Limb Ischemia (CLI) Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Critical Limb Ischemia (CLI) Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Critical Limb Ischemia (CLI) Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Critical Limb Ischemia (CLI) Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Critical Limb Ischemia (CLI) Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Critical Limb Ischemia (CLI) Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Critical Limb Ischemia (CLI) Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Critical Limb Ischemia (CLI) Treatment Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Critical Limb Ischemia (CLI) Treatment Market Segmentation

By Treatment Modality
Peripheral Revascularization Devices
Pharmacological
Regenerative & Cell-Based Therapies
By Device Type
Peripheral Dilatation Balloons
Vascular and Drug-Eluting Stents
Atherectomy Systems & Catheters
Embolic Protection Devices
By Drug Class
Antiplatelet Drugs
Antithrombotic
Lipid-Lowering Agents
Antihypertensive Agents
By Route of Drug Administration
Oral Administration
Parenteral
By End-User
Hospitals and Tertiary Medical Centers
Ambulatory Surgical Centers
Specialty Vascular and Wound-Care Clinics

Top Companies in Critical Limb Ischemia (CLI) Treatment Industry

Medtronic plc
Boston Scientific Corporation
Abbott Laboratories
Cook Medical LLC
Becton, Dickinson and Company (BD)
Koninklijke Philips N.V.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Terumo Corporation
Cardiovascular Systems, Inc. (An Abbott Company)
Biotronik SE & Co. KG

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025